DE69821740D1 - Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd - Google Patents

Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd

Info

Publication number
DE69821740D1
DE69821740D1 DE69821740T DE69821740T DE69821740D1 DE 69821740 D1 DE69821740 D1 DE 69821740D1 DE 69821740 T DE69821740 T DE 69821740T DE 69821740 T DE69821740 T DE 69821740T DE 69821740 D1 DE69821740 D1 DE 69821740D1
Authority
DE
Germany
Prior art keywords
hemoglobin
oxyd
nitrogen
erythrocytes
containing erythrocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69821740T
Other languages
English (en)
Other versions
DE69821740T2 (de
Inventor
Takashi Yonetani
Antonio Tsuneshige
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FORYOU CORP., YOKOHAMA, KANAGAWA, JP
Original Assignee
Foryou Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foryou Corp filed Critical Foryou Corp
Publication of DE69821740D1 publication Critical patent/DE69821740D1/de
Application granted granted Critical
Publication of DE69821740T2 publication Critical patent/DE69821740T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69821740T 1997-07-03 1998-07-03 Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd Expired - Fee Related DE69821740T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5168097P 1997-07-03 1997-07-03
US51680P 1997-07-03
PCT/JP1998/003002 WO1999001146A1 (en) 1997-07-03 1998-07-03 Treatment of hemoglobin containing erythrocytes with nitric oxide

Publications (2)

Publication Number Publication Date
DE69821740D1 true DE69821740D1 (de) 2004-03-25
DE69821740T2 DE69821740T2 (de) 2005-03-17

Family

ID=21972754

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69821740T Expired - Fee Related DE69821740T2 (de) 1997-07-03 1998-07-03 Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd

Country Status (7)

Country Link
US (1) US6087087A (de)
EP (1) EP0948337B1 (de)
JP (1) JP3568541B2 (de)
AT (1) ATE259644T1 (de)
CA (1) CA2264792A1 (de)
DE (1) DE69821740T2 (de)
WO (1) WO1999001146A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2381205C (en) * 1999-08-02 2010-05-11 Duke University Method for determining physiological effects of hemoglobin
US20030228564A1 (en) * 2001-05-30 2003-12-11 Edrich Richard Alan Nitric oxide in a pathogen inactivation process
KR20040086267A (ko) * 2002-01-11 2004-10-08 데이비드 알. 휘트록 암모니아 산화 박테리아를 포함하는 조성물 및 그를사용하는 방법
EP1514103A4 (de) * 2002-05-29 2006-05-24 Univ Duke Messung von stickstoffmonoxid in blutgasen und darauf beruhende behandlungen
WO2004054433A2 (en) 2002-12-12 2004-07-01 Duke University Forming iron nitrosyl hemoglobin
US20070148136A1 (en) * 2003-09-26 2007-06-28 Whitlock David R Methods of using ammonia oxidizing bacteria
CN1905901A (zh) * 2004-01-29 2007-01-31 学校法人庆应义塾 红细胞功能修饰物质
CA2600927C (en) 2005-03-07 2017-04-18 Sangart, Inc. Compositions and methods for delivering carbon monoxide (co) and nitric oxide (no) to tissue using heme proteins as carriers
US9199026B2 (en) * 2011-01-07 2015-12-01 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
BR112013023740A2 (pt) 2011-03-16 2016-08-02 Dynasil Biomedical Corp métodos e materiais para prolongamento da armazenagem útil de preparações de glóbulo vermelho e preparações de plaqueta
JP6389125B2 (ja) * 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 赤血球の処理法
US9375525B2 (en) 2012-01-09 2016-06-28 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
GB201207543D0 (en) * 2012-05-01 2012-06-13 Haemair Ltd Treatment of transfusion blood
EP3967143A1 (de) * 2013-02-28 2022-03-16 Hemanext Inc. Gasanreicherungsvorrichtung zur blutbehandlung und zugehöriges verfahren
WO2015179602A1 (en) * 2014-05-21 2015-11-26 Albert Einstein College Of Medicine, Inc. Compositions and methods for enhancing red blood cell storage time and survivability using nitric oxide releasing hybrid hydrogel nanoparticles
US10194871B2 (en) 2015-09-25 2019-02-05 Sanmina Corporation Vehicular health monitoring system and method
US10750981B2 (en) 2015-09-25 2020-08-25 Sanmina Corporation System and method for health monitoring including a remote device
US9636457B2 (en) 2015-07-19 2017-05-02 Sanmina Corporation System and method for a drug delivery and biosensor patch
US10932727B2 (en) 2015-09-25 2021-03-02 Sanmina Corporation System and method for health monitoring including a user device and biosensor
US10321860B2 (en) 2015-07-19 2019-06-18 Sanmina Corporation System and method for glucose monitoring
US10744261B2 (en) 2015-09-25 2020-08-18 Sanmina Corporation System and method of a biosensor for detection of vasodilation
US10736580B2 (en) 2016-09-24 2020-08-11 Sanmina Corporation System and method of a biosensor for detection of microvascular responses
US10973470B2 (en) 2015-07-19 2021-04-13 Sanmina Corporation System and method for screening and prediction of severity of infection
US10952682B2 (en) 2015-07-19 2021-03-23 Sanmina Corporation System and method of a biosensor for detection of health parameters
US9788767B1 (en) 2015-09-25 2017-10-17 Sanmina Corporation System and method for monitoring nitric oxide levels using a non-invasive, multi-band biosensor
US10888280B2 (en) 2016-09-24 2021-01-12 Sanmina Corporation System and method for obtaining health data using a neural network
US10945676B2 (en) 2015-09-25 2021-03-16 Sanmina Corporation System and method for blood typing using PPG technology
US10466783B2 (en) 2018-03-15 2019-11-05 Sanmina Corporation System and method for motion detection using a PPG sensor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280454T3 (es) * 1992-02-07 2007-09-16 Vasogen Ireland Limited Metodo para aumentar la concentracion de oxido nitrico en la sangre.
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
JP2002513400A (ja) * 1997-02-06 2002-05-08 デューク ユニバーシティ メディカル センター Ｎｏ修飾ヘモグロビンおよびそのための使用

Also Published As

Publication number Publication date
US6087087A (en) 2000-07-11
WO1999001146A1 (en) 1999-01-14
ATE259644T1 (de) 2004-03-15
DE69821740T2 (de) 2005-03-17
EP0948337A1 (de) 1999-10-13
EP0948337B1 (de) 2004-02-18
CA2264792A1 (en) 1999-01-14
JP2001507375A (ja) 2001-06-05
JP3568541B2 (ja) 2004-09-22

Similar Documents

Publication Publication Date Title
DE69821740D1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
EP0277428A3 (de) Kosmetische Zusammensetzung
DE69923671D1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
EP0502113A4 (en) Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
CA2251530A1 (en) Treatment of a hemoglobinopathy
MXPA03009905A (es) EMPLEO DE COMPUESTOS DE COMPLEJOS METALICOS COMO CATALIZADORES DE OXIDACIoN.
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
DE3781177D1 (de) Gemischte phosphorsaeurediester, ihre herstellung und verwendung als entzuendungshemmende mittel.
DE69714253D1 (de) Stickstoffoxydabgebendes präparat zur reduzierung der toxizität von wirkstoffen
ES2037669T3 (es) Un procedimiento para preparar una sustancia que se une a la trombina.
DE69327236T2 (de) Verwendung von diätetischen molkeproteinen zur behandlung von hiv seropositiven individuen
ATE70450T1 (de) Zusammensetzungen aus vanadium und peroxyd als nachahmungsmittel von insulin.
DK0559655T3 (da) Med imidoester tværbundne hæmoglobinpræparater
IL87707A0 (en) Hemoglobin-based blood substitute and method for the preparation thereof
ATE74765T1 (de) Eine enzymzusammensetzung als verdauungsbeschleuniger bei verschiedenen spiegeln im verdauungskanal und deren herstellungsverfahren.
ATE222600T1 (de) Expression von rekombinantem hämoglobin in hefe
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
SE8500470L (sv) Kompositioner for kosmetiskt, helso- och kroppsbevarande bruk
ATE499944T1 (de) Verwendung von einem extrakt von einem nicht- photosynthetischen faserigen bakterium zur beförderung der herstellung von superoxid- dismutase
HUP0102217A2 (hu) Megnövelt cinkmegkötő képességű új inzulinanalógok
ATE207932T1 (de) Komplexe aus porphyrin und menschlichem serumalbumin mit der fähigkeit, sauerstoff zu binden, und deren therapeutische verwendungen
DE69809587T2 (de) Konzentrat für medizinische lösung und dessen verwendung
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
CA2135739A1 (en) Hemoglobin-Enzyme Complexes
ATE140389T1 (de) Hämoglobin-oligomer basierte komposition und seine herstellung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: FORYOU CORP., YOKOHAMA, KANAGAWA, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee